David M. Epstein
Founder, President & Chief Executive Officer at Black Diamond Therapeutics
Stony Brook, US
About
David M. Epstein, PhD is founder & CEO of Black Diamond Therapeutics. David is a biopharma leader and executive who has successfully led large and small R&D teams in academic, virtual, start-up, mid-size and global large-pharma settings. His teams have progressed multiple novel agents through development in oncology, cardiovascular disease, and retinal degeneration. David was Chief Scientific Officer at Astellas/OSI Pharmaceuticals, and previously a founder of Archemix Corp. Most recently Vice Dean, Innovation & Entrepreneurship, and Associate Professor in Cancer & Stem Cell Biology at Duke-NUS Medical School, Singapore, David founded and built Duke-NUS’s Centre for Technology & Development (CTeD). The Centre has developed a pipeline of innovation projects, completing 2 product-development biopharma partnerships, and 7 spin-outs from its technologies. David’s research focuses on RNA splicing and immune-tumor cell interactions in cancer. He earned a Ph.D. in Biochemistry at Brandeis U
Position in the VCSift Database
- • 2 investors at Black Diamond Therapeutics are tracked.
- • 7 investors hold the Founder, President & Chief Executive Officer role in VCSift. David M. Epstein is one of them.
- • 2 investors are based in Stony Brook, New York, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- Stony Brook, US
Contact Information
Find more investors like David
Search Investors